The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693

British Journal of Clinical Pharmacology

Volumn 60, Issue 2, 2005, Pages 128-136

  Van Der Post, J P ^a   De Visser, S J ^a   De Kam, M L ^a   Woelfler, M ^a   Hilt, D C ^b   Vornov, J ^b   Burak, E S ^b   Bortey, E ^b   Slusher, B S ^b   Limsakun, T ^b   Cohen, A F ^a   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

Central nervous system; NAALAD ase inhibitor; Pharmacokinetics

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GPI 5693; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; ENZYME INHIBITION; ERUCTATION; EYE MOVEMENT; FATIGUE; FEMALE; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MALE; MENTAL DISEASE; NAUSEA; NEUROPATHIC PAIN; NORMAL HUMAN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SKIN APPENDAGE DISEASE; SKIN DISEASE; SKIN MANIFESTATION; SOMNOLENCE; VISUAL ANALOG SCALE; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADULT; AFFECT; AREA UNDER CURVE; AWARENESS; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; EATING; ELECTROENCEPHALOGRAPHY; FEMALE; GASTROINTESTINAL DISEASES; GLUTAMATE CARBOXYPEPTIDASE II; GLUTARATES; HUMANS; MALE; SEX FACTORS; SULFHYDRYL COMPOUNDS;

EID: 23044458183     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02396.x     Document Type: Article

References (20)

1. Jackson PF, Slusher BS. Design of NAALADase inhibitors: a novel neuroprotective strategy. Curr Med 2001; 8: 949-57.
2. Jackson PF, Tays KL, Maclin KM, Ko YS, Li W, Vitharana D, Tsukamoto T, Stoermer D, Lu XC, Wazniak K, Slusher BS. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem 2001; 44: 4170-5.
3. Zhang W, Slusher B, Murakawa Y, Wazniak K, Tsukamoto T, Jackson PF, Sima AA. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 2002; 194: 21-8.
4. Slusher BS, Thomas A, Paul M, Schad CA, Ashby CR Jr. Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated-alpha-linked-acidic dipeptidase (NAALADASE). Synapse 2001; 41: 22-8.
5. Slusher BS, Vornov JJ, Thomas AG, Hum PD, Hacubuni I, Bhaedwaj A, Traystman RJ, Robinson MD, Britton P, Lu XC, Tortella FC, Wazniak KM, Yudhoff M, Potter BM, Jackson PF. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999; 5: 1396-402.
6. Wauquier A. EEG and neuropharmacology. In: Electroencephalography - Basic Principles, Clinical Applications, and Related Fields, 3rd Edition., ed. Niedermeyer E, Lopez da Silva F, Baltimore: Williams & Wilkins 1993, 619-29.
7. Saletu B, Grünberger J, Anderer P, Linzmayer L, König P. On the cerebro-protective effects of caroverine, a calcium-channel blocker and antiglutaminergic drug: double-blind, placebo-controlled, EEC-mapping and psychometric studies under hypoxia. Br J Clin Pharmacol 1996; 41: 89-99.
8. van Steveninck AL. Methods of assessment of central nervous system effects of drugs in man. Thesis, State University Leiden 1993.
9. Van Steveninck AL, Schoemaker RC, Pieters MSM, Kroon JM, Breimer DD, Cohen AF. A study comparing the sensitivities of adaptive tracking, eye movement analysis and visual analogue lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 1991; 50: 172-80.
10. Van Steveninck AL, Van Berckel BNM, Schoemaker RC, Breimer DD, Van Gerven JMA, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol 1999; 13: 10-7.
11. Hartvig P, Valtysson J, Lindner K-J, Knstensen J, Karlsten R, Bustafsson LL, Persson J, Svensson JO, Oye I, Antoni G. Central nervous system effects of subdissociative doses of (s)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995; 58: 165-73.
12. Harborne GC, Watson FL, Healy DT, Groves L. The effects of sub-anaesthetic doses of ketamine on memory, cognitive performance and subjective experience in healthy volunteers. J Psychopharmacol 1996; 10: 134-40.
13. Cohen AF, Ashby L, Crowley D, Land G, Peck AW. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985; 20: 619-29.
14. Muir KW, Grosset DG, Gamzu E, Lees KR. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol 1994; 38: 33-8.
15. van Steveninck AL, Cohen AF, Ward T. A microcomputer based system for recording and analysis of smooth pursuit and saccadic eye movements. Br J Clin Pharmacol 1989; 27: 712-3.
16. Borland RG, Nicholson AN. Visual motor coordination and dynamic visual acuity. Br J Clin Pharmacol 1984; 18: 69S-72S.
17. Wright BM. A simple mechanical ataxia-meter. J Physiol 1971; 218: 27P-28P.
18. Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 1971; 10: 181-91.
19. Bond A, Lader M. Self-concepts in anxiety states. Br J Med Psychol 1976; 49: 275-9.
20. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 1998; 88: 82-8.